本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300955 证券简称：嘉亨家化 公告编号：2025-039 嘉亨家化股份有限公司 关于筹划控制权变更事项进展暨继续停牌的公告 公司指定的信息披露媒体为《证券时报》《中国证券报》《证券日报》和巨 潮资讯网（http://www.cninfo.com.cn），公司所有信息均以在上述媒体刊登的公 告为准。 敬请广大投资者理性投资，注意投资风险。 特此公告。 嘉亨家化股份有限公司 一、停牌情况概述 嘉亨家化股份有限公司（以下简称"公司"）于 2025 年 12 月 24 日收到控股 股东曾本生先生的通知，获悉控股股东曾本生先生正在筹划控制权变更相关事宜， 该事项可能导致公司控股股东、实际控制人发生变更。经公司向深圳证券交易所 申请，公司股票（证券简称：嘉亨家化，证券代码：300955）自 2025 年 12 月 25 日（星期四）开市起停牌，预计停牌时间不超过 2 个交易日。具体内容详见 公司于 2025 年 12 月 24 日刊登在巨潮资讯网（http://www.cninfo.com.cn）上的《关 于筹 ...

Core Viewpoint - Jiaheng Jiahua is planning a change in control, leading to a temporary suspension of its stock trading, amid ongoing performance deterioration since the second generation took over a year ago [1][3][6]. Group 1: Control Change Announcement - On December 24, Jiaheng Jiahua announced that it would suspend trading of its stock starting December 25 due to a planned change in control [1][3]. - The controlling shareholder, Zeng Bensheng, is in discussions regarding the change, which may result in a shift in the company's actual controller [3][8]. Group 2: Stock Performance - On the announcement day, Jiaheng Jiahua's stock price surged over 13% during trading, closing at 41.51 yuan per share, with a market capitalization of 4.18 billion yuan [3][8]. - The stock has seen a year-to-date increase of 167% [3][8]. Group 3: Company Background - Jiaheng Jiahua specializes in OEM/ODM for daily chemical products and the design and production of plastic packaging containers, serving well-known global and domestic brands [3][8]. - The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market in March 2021 [3][8]. Group 4: Management Transition - In November 2024, the company completed a board restructuring, with Zeng Bensheng stepping back and his son, Zeng Huanbin, becoming the chairman and continuing as general manager [3][8]. - Zeng Bensheng's daughter, Zeng Yapin, was appointed as vice chairman and vice general manager, marking the completion of the second-generation succession [3][8]. Group 5: Financial Performance - Jiaheng Jiahua has experienced continuous revenue decline, with revenues dropping by 9.45% in 2022 and 3.41% in 2023, while net profit fell by 28.25% and 42.39% respectively [4][9]. - In 2024, the company reported its first loss since going public, with a loss of 23.697 million yuan and a revenue decline of 9.13% [4][9]. - For the first three quarters of this year, the company achieved a revenue of 860 million yuan, a year-on-year increase of 24.42%, but reported a net loss of 29.5005 million yuan, exceeding the total loss of the previous year [10].

Core Viewpoint - The company, Jiaheng Jiahua, is undergoing a potential change in control as notified by its controlling shareholder, Zeng Bensheng, which may lead to a change in the company's actual controller [1]. Company Summary - Jiaheng Jiahua is primarily engaged in the research, design, and production of daily chemical products (OEM/ODM) and plastic packaging containers, providing integrated services for cosmetics and household care products [3]. - The company's main products include skincare, hair care, perfumes, soaps, disinfectants, and hand sanitizers, with major clients including well-known companies such as Kefu, Beitaini, and Procter & Gamble [4]. Financial Performance - In the first three quarters of 2025, Jiaheng Jiahua reported revenue of 859.6 million yuan, representing a year-on-year growth of 24.42%, but incurred a net loss of 29.5 million yuan [4]. - The cosmetics industry showed signs of recovery in 2025, despite a slight decline in growth compared to the overall retail sales of consumer goods [4].

Group 1 - Guangqi Technology's controlling shareholder proposed a share buyback of 50 million to 100 million yuan for employee stock ownership plans or equity incentives [1] - Xingyuan Zhuomai received a supplier designation from a domestic electric vehicle manufacturer to develop and supply reducer shell components, with expected sales of approximately 575 million yuan over four years from 2027 to 2030 [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Hongda Electronics disclosed uncertainty regarding the IPO progress of its associate Jiangsu Zhanxin, in which it holds a 13.79% stake [4] - Kangchen Pharmaceutical received FDA approval to conduct clinical trials for its KC1086 project, aimed at treating advanced recurrent or metastatic solid tumors [5] - Kweichow Moutai adjusted its share buyback price ceiling to 1863.67 yuan per share, effective from December 19, 2025 [6] Group 3 - Mousse Co. announced that its controlling shareholder and actual controllers committed not to reduce their holdings within one year [7] - Tongxingbao's subsidiary signed a business contract worth 43.166 million yuan for a cloud expansion project [8] - Kaifa Electric announced plans for three shareholders to collectively reduce their holdings by 0.6999% [9] Group 4 - Longpan Technology plans to increase the production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [10] - Zhuhai Guanyu announced plans for two shareholders to reduce their holdings by up to 3% [11] - Jiaheng Home Textiles is planning a change in control, leading to a temporary suspension of its stock [12] Group 5 - Kehua Bio's subsidiary received a medical device registration certificate for a gene polymorphism detection kit [13] - Saitex New Materials' actual controller plans to reduce holdings by up to 3% [14] - Sanhui Electric announced a shareholder's plan to reduce holdings by up to 2% [15] Group 6 - Binhua Co. plans to establish a venture capital fund with a total scale of 400 million yuan, focusing on strategic emerging industries [16] - Jindun Co. announced plans for two shareholders to reduce their holdings by up to 4% [17] - Hengdian East Magnetic's controlling shareholder plans to reduce holdings by up to 1% [18][19] Group 7 - Luxin Investment's controlling shareholder plans to reduce holdings by up to 1% [20] - Huakang Clean announced a joint bid for a hospital procurement project worth 157 million yuan [21] - Xuedilong plans to reduce its repurchased shares by up to 488,560 shares [22] Group 8 - Enhua Pharmaceutical's subsidiary signed an exclusive commercial cooperation agreement for three long-acting antipsychotic products [23] - Aier Eye Hospital plans to acquire partial equity in 39 institutions for a total of 963 million yuan [24] - Gaozheng Mining plans to acquire 100% equity of Overseas Explosives for 510 million yuan [25] Group 9 - Donghong Co. plans to repurchase shares worth 30 million to 60 million yuan for employee stock ownership plans [26] - Bear Electric's controlling shareholder plans to reduce holdings by up to 0.64% [27] - *ST Zhengping announced the initiation of pre-restructuring by the Xining Intermediate Court [28][29] Group 10 - Caesar Travel's shareholder plans to reduce holdings by up to 3% [30] - Lianchuang Electronics announced a change in controlling shareholder to Jiangxi State-owned Assets Supervision and Administration Commission [31] - Beixin Road and Bridge plans to transfer 5.33% equity in Henan Yuhang for 243 million yuan [32] Group 11 - Fenglong Co. is planning a change in control, with stock resuming trading [33]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 停牌期间，公司将根据上述事项进展情况，严格按照有关法律法规的规定和要求履行信息披露义务。待 上述事项确定后，公司将及时发布相关公告并申请股票复牌。 公司指定的信息披露媒体为《证券时报》《中国证券报》《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn），公司所有公开披露的信息以上述媒体刊登的信息为准。 敬请广大投资者理性投资，注意投资风险。 特此公告。 特别提示： 1、嘉亨家化股份有限公司（以下简称"本公司"、"公司"）控股股东曾本生先生正在筹划控制权变更相 关事宜，该事项可能导致公司控股股东、实际控制人发生变更。经公司向深圳证券交易所申请，公司股 票（证券简称：嘉亨家化，证券代码：300955）自2025年12月25日（星期四）开市起停牌，预计停牌时 间不超过2个交易日。 2、本次交易事项能否最终实施完成及实施结果尚存在不确定性，敬请广大投资者注意投资风险。 公司于2025年12月24日收到控股股东曾本生先生的通知，获悉控股股东曾本生先生 ...

Core Viewpoint - Jiahen Jiahua is planning a change in control, leading to a potential shift in its major shareholder and actual controller, with stock suspension starting from December 25, 2025, for up to two trading days [2] Group 1: Company Control Change - The company announced that its controlling shareholder, Zeng Bensheng, is in the process of planning a change in control, which may result in a change of the company's major shareholder and actual controller [2] - The matter is still in the planning stage, with significant uncertainty, and all parties are discussing specific plans and agreements [2] Group 2: Company Products and Clients - Jiahen Jiahua's product range includes skincare, hair care, perfumes, household care products like soap and disinfectants, and associated plastic packaging [2] - Major clients include well-known domestic and international brands such as Beitaini, Shanghai Jahwa, Yumaiting, Reckitt, Victoria's Secret, DoTerra, Procter & Gamble, Johnson & Johnson, and Shell [2] Group 3: Leadership Transition - In November 2024, Zeng Bensheng was granted the title of honorary chairman for life and stepped down from his roles as chairman and legal representative, with his son, Zeng Huanbin, taking over [2] - Zeng Bensheng's daughter, Zeng Yaping, has also joined the board as vice general manager and vice chairman, marking the official transition to the "second generation" leadership [3] Group 4: Financial Performance - For the first three quarters of 2025, Jiahen Jiahua reported revenue of 860 million yuan, a year-on-year increase of 24.42%, but a net profit loss of 29.5 million yuan, a dramatic decline of 1430.74% [3] - This marks the first loss in net profit attributable to the parent company in the first three quarters over the past five years [3] Group 5: Reasons for Profit Decline - The significant decline in net profit is attributed to changes in product sales structure and increased fixed costs from depreciation and amortization at Huzhou Jiahen [5] - Increased management expenses due to higher employee compensation and rising interest expenses from expanded bank loans have also contributed to the increase in period costs [5] Group 6: Stock Market Reaction - On December 24, 2025, Jiahen Jiahua's stock price surged, increasing by over 13% at one point, and closing up 8.32% at 41.51 yuan per share, with a total market value of 4.184 billion yuan [6]

Core Viewpoint - Jiaheng Jiahua is planning a change in control, leading to a potential shift in its major shareholder and actual controller, with stock suspension starting from December 25, 2025, for up to two trading days [1] Group 1: Company Control Change - The company announced that its controlling shareholder, Zeng Bensheng, is in the process of planning a change in control, which may result in a change of the major shareholder and actual controller [1] - The matter is still in the planning stage, with significant uncertainty, and parties are negotiating specific plans and agreements [1] Group 2: Company Performance - In the first three quarters of 2025, Jiaheng Jiahua reported revenue of 860 million yuan, a year-on-year increase of 24.42%, but a net loss of 29.5 million yuan, a dramatic decline of 1430.74% [3][5] - This marks the first time in five years that the company has reported a net loss in the first three quarters [3] Group 3: Financial Factors - The significant decline in net profit is attributed to changes in product sales structure, increased depreciation and amortization expenses, and rising management costs due to employee compensation and increased interest expenses from expanded bank loans [5] Group 4: Market Reaction - On December 24, 2025, the company's stock price surged, increasing by over 13% at one point, and closing up 8.32% at 41.51 yuan per share, with a total market capitalization of 4.184 billion yuan [6]

【导读】嘉亨家化筹划易主，12月25日起停牌 中国基金报记者 牛思若 1 2月24日，嘉亨家化公告 称 ，公司控股股东曾本生正在筹划控制权变更，可能导致公司控股股东及实际控制人发生变更。经申请，公司 股票自2025年12月25日起停牌，预计不超过2个交易日。 嘉亨家化表示，目前，该事项尚处于筹划中，存在重大不确定性，各方主体正在就具体方案、协议等相关事项进行论证和磋商，具体情况 以各方签订的相关协议为准。 公开资料显示，嘉亨家化的产品包括护肤类、洗护类、香水等化妆品，香皂、消毒液、洗手液等家庭护理产品，以及配套的塑料包装容 器，主要客户包括贝泰妮、上海家化、郁美净、利洁时、维多利亚的秘密、多特瑞、宝洁、强生、壳牌等国内外知名品牌。 2024年11月，嘉亨家化曾发布公告称，创始人曾本生获授终身名誉董事长称号，并卸任公司董事长、法定代表人职务，这两个职位均由其 子曾焕彬接任。 此外，曾本生之女曾雅萍首次进入董事会名单中，担任公司副总经理、副董事长。这意味着，嘉亨家化正式进入"二代接班"的新阶段。 从业绩来看，"二代接班"后的嘉亨家化表现并不理想。2025 年前三季度，嘉亨家化实现营收8.6亿元，同比增长24.42 ...

Group 1 - Spring Technology has received a procurement order for robot products from Lexiang Technology amounting to 43.2628 million yuan, marking recognition of its manufacturing technology and laying the foundation for future business expansion in robot products [1] - Huayin Technology signed a framework procurement contract worth 254 million yuan for special functional materials for aircraft fuselage, reflecting the implementation of its strategic layout and enhancing its market position in key materials for aviation engines [2] - Wankai New Materials' subsidiary signed a procurement contract with Lingxin Qiaoshou to provide lightweight components for humanoid robot arms, with a total contract value of 10 million yuan [2] Group 2 - Heng Rui Medicine's injectable SHR-A1904 has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, with no similar products approved globally, targeting specific cancer types [3] - Hongda Electronics announced that its indirect holding in Jiangsu Zhanxin's IPO application has been accepted, but the subsequent progress remains uncertain [4] - Jia Heng Jia Hua's controlling shareholder is planning a change in control, leading to a temporary suspension of its stock trading [5]

Group 1 - Fenglong Co., Ltd. announced that its controlling shareholder will change to UBTECH, and the stock will resume trading [12][13] - Victory Energy has experienced a continuous increase in stock price for nine consecutive trading days, with a cumulative increase of 135.86%, and may apply for a trading suspension if the price continues to rise [4] - Dongbai Group issued a stock price fluctuation announcement, indicating potential risks of significant price drops after recent increases [10] Group 2 - Enhua Pharmaceutical's wholly-owned subsidiary signed a $20 million exclusive commercial cooperation agreement with Green Leaf Pharmaceutical for three long-acting antipsychotic products in mainland China, with a sales target of at least 2.7 billion RMB from 2026 to 2035 [2] - Longpan Technology plans to increase the planned production capacity of lithium iron phosphate cathode materials from 62,500 tons per year to 100,000 tons per year [2] - Jiangsu Zhanchin, a company in which Hongda Electronics holds a 13.79% stake, has submitted an IPO application, but the progress remains uncertain [3] Group 3 - Jizhi Co., Ltd. intends to acquire at least 51% of Zhejing Pumai Technology to enhance its capabilities in the robotics sector [4] - Nanshan Aluminum established a wholly-owned subsidiary in Hainan with an investment of 5 million RMB to improve regional industrial layout and expand high-end aluminum product development [5] - Sany Heavy Energy plans to use up to 9.5 billion RMB of its own funds for entrusted wealth management in 2026 [9] Group 4 - Zongtai Automobile reached a settlement with two bank creditors to avoid large financial disputes and facilitate the release of frozen assets [11] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, but the project faces risks of underperformance [6] - Guangyang Co., Ltd. signed a strategic cooperation agreement with Konghui Automotive to advance its business layout in the intelligent driving sector [7]